1. Home
  2. HON vs REGN Comparison

HON vs REGN Comparison

Compare HON & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Honeywell International Inc.

HON

Honeywell International Inc.

HOLD

Current Price

$228.19

Market Cap

69.8B

Sector

Industrials

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$661.88

Market Cap

68.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HON
REGN
Founded
1885
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8B
68.6B
IPO Year
2012
1995

Fundamental Metrics

Financial Performance
Metric
HON
REGN
Price
$228.19
$661.88
Analyst Decision
Buy
Buy
Analyst Count
13
25
Target Price
$249.92
$830.16
AVG Volume (30 Days)
5.3M
955.8K
Earning Date
04-23-2026
04-29-2026
Dividend Yield
2.26%
0.55%
EPS Growth
N/A
8.19
EPS
1.29
6.75
Revenue
$36,529,000,000.00
$5,872,227,000.00
Revenue This Year
$6.74
$12.45
Revenue Next Year
$5.91
$10.13
P/E Ratio
$173.08
$98.97
Revenue Growth
12.92
20.82
52 Week Low
$186.76
$541.00
52 Week High
$252.00
$821.11

Technical Indicators

Market Signals
Indicator
HON
REGN
Relative Strength Index (RSI) 52.60 58.46
Support Level $220.64 $593.21
Resistance Level $242.65 $664.00
Average True Range (ATR) 8.87 15.03
MACD -0.35 7.36
Stochastic Oscillator 28.41 81.69

Price Performance

Historical Comparison
HON
REGN

About HON Honeywell International Inc.

Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: